No Clinical Benefit Suggested by Addition of Pulmozyme to Treatment of Critically Ill Patients With COVID-19 in I-SPY COVID Trial

SAN FRANCISCO, Jan. 10, 2022. Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the Pulmozyme (dornase alfa) arm of the trial has been terminated. The interim analysis suggests that the addition of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials